Stock SKAN SKAN GROUP AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SKAN Group AG

Equities

SKAN

CH0013396012

Market Closed - Swiss Exchange
Other stock markets
 11:30:06 2024-07-16 am EDT 		5-day change 1st Jan Change
79.2 CHF -0.25% Intraday chart for SKAN Group AG -0.50% -1.98%
May. 31 Skan Group Boosts Interest in Belgian Unit Aseptic Technologies to 90% MT
Mar. 26 Transcript : SKAN Group AG, 2023 Earnings Call, Mar 26, 2024

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

  • With an expected P/E ratio at 51.23 and 36.17 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's enterprise value to sales, at 4.45 times its current sales, is high.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SKAN GROUP AG Stock SKAN Group AG
-1.98% 2B -
SHOCKWAVE MEDICAL Stock Shockwave Medical
+75.67% 12.57B -
B-
PENUMBRA, INC. Stock Penumbra, Inc.
-21.89% 7.43B
C+
MASIMO CORPORATION Stock Masimo Corporation
-6.22% 5.79B
C-
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD. Stock Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
+8.16% 5.09B
D+
GETINGE AB Stock Getinge AB
-17.37% 4.78B
B
APT MEDICAL INC. Stock APT Medical Inc.
+16.22% 4.2B -
ASAHI INTECC CO., LTD. Stock Asahi Intecc Co., Ltd.
-15.15% 4.13B
B-
INARI MEDICAL, INC. Stock Inari Medical, Inc.
-10.75% 3.19B
C
NOVOCURE LIMITED Stock NovoCure Limited
+29.27% 1.94B
C-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SKAN Stock
  4. Ratings SKAN Group AG